Phase II Study of Everolimus Beyond Progression
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Estrogen Receptor-positive Breast Cancer|HER2-negative Breast Cancer|Progesterone Receptor-positive Breast Cancer|Recurrent Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer
Interventions: DRUG: everolimus|DRUG: anastrozole|DRUG: letrozole|DRUG: tamoxifen citrate|DRUG: fulvestrant|DRUG: megestrol acetate
Sponsor: Emory University
Collaborators: Novartis